SHR7280 Tablets

Phase 1Completed

0 watching 0 views this week💤 Quiet

Hype Score

Development Stage

✓

Pre-clinical

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Endometriosis

Conditions

Endometriosis, Uterine Fibroids, Assisted Reproduction

Trial Timeline

Apr 28, 2025 → Jun 5, 2025

NCT ID

NCT06949124

About SHR7280 Tablets

SHR7280 Tablets is a phase 1 stage product being developed by Jiangsu Hengrui Medicine for Endometriosis. The current trial status is completed. This product is registered under clinical trial identifier NCT06949124. Target conditions include Endometriosis, Uterine Fibroids, Assisted Reproduction.

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (2)

NCT ID	Phase	Status	Start	Completion	Indication
NCT06949124	Phase 1	Completed	Apr 28, 2025	Jun 5, 2025	Endometriosis
NCT05082233	Phase 2	Completed	Mar 6, 2022	Aug 3, 2023	Female Subjects Undergoing COH in ART to Prevent Early Ovulation

Competing Products

20 competing products in Endometriosis

See all competitors

Product	Company	Stage	Hype Score
ASP1707 + Placebo + Leuprorelin acetate	Astellas Pharma	Phase 2	52
40 mg relugolix, 1 mg estradiol, 0.5 mg norethindrone acetate	Sumitomo Pharma	Phase 3	77
SHR7280 tablets + SHR7280 dry suspension	Jiangsu Hengrui Medicine	Phase 1	33
SHR7280 + Placebo oral tablet	Jiangsu Hengrui Medicine	Phase 1/2	41
SHR7280 Tablet + SHR7280 Placebo Tablet	Jiangsu Hengrui Medicine	Phase 1	33
Placebo + Elagolix	AbbVie	Phase 2	52
Elagolix + Placebo + Combined Oral Contraceptive	AbbVie	Phase 3	77
Estradiol/Norethindrone Acetate + Placebo for Elagolix + Elagolix + Placebo for E2/NETA	AbbVie	Phase 3	77
Elagolix	AbbVie	Phase 3	77
elagolix + estradiol/norethindrone acetate (E2/NETA)	AbbVie	Phase 3	77
Elagolix + placebo	AbbVie	Phase 2	52
Elagolix	AbbVie	Phase 3	77
Elagolix + Subcutaneous depot medroxyprogesterone acetate (DMPA-SC) + Placebo to Elagolix + Placebo to DMPA-SC	AbbVie	Phase 2	52
elagolix	AbbVie	Phase 3	77
Elagolix	AbbVie	Phase 3	77
Leuprorelin Acetate Depot + Elagolix + Placebo to Elagolix + Placebo to Leuprorelin Acetate	AbbVie	Phase 2	52
Gefapixant + Placebo + Naproxen	Merck	Phase 2	52
BGS649 + Placebo	Novartis	Phase 2	52
Active treatment with a high dose of BGS649 + Active treatment with a low dose of BGS649 + Placebo treatment to blind study	Novartis	Phase 2	52
Letrozole	Novartis	Phase 2	52

Other Products from Jiangsu Hengrui Medicine

ApatinibApproved

Remimazolam TosilateApproved

Henagliflozin 10 mg daily + Metformin 1700 mg dailyApproved

ImrecoxibApproved

IvarmacitinibApproved